Bomyntra Injection
Product Images NDC 65219-672

11 FDA label images from Fresenius Kabi Usa, Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Bomyntra (NDC 65219-672). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Fresenius Kabi Usa, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure (Tra1b 0002 01)

Figure (Tra1b 0002 01)
An instructional diagram showing a labeled BOMYNTRA 70 mg/mL liquid-filled syringe for subcutaneous injection before and after use. Key parts identified include the needle cap, clear needle guard, liquid-filled syringe barrel, plunger, needle covered after use, and needle guard spring extension post-injection.*
FDA Label Image

Figure A (Tra1b 0002 02)

Figure A (Tra1b 0002 02)
An instructional illustration showing a person removing the cap from a syringe containing medication, preparing it for injection. The syringe is held in one hand, and the cap is being pulled off with the other hand, indicated by a purple arrow pointing upward. This image is related to the subcutaneous injection process for BOMYNTRA (Denosumab).*
FDA Label Image

Figure B (Tra1b 0002 03)

Figure B (Tra1b 0002 03)
Diagram showing recommended injection sites for BOMYNTRA (Denosumab) 70 mg/mL injection. The marked areas include the upper outer arms (both arms) and the upper outer thighs (front view). The illustration indicates subcutaneous injection locations on a human figure from front and back views.*
FDA Label Image

Figure C (Tra1b 0002 04)

Figure C (Tra1b 0002 04)
An instructional illustration showing the administration of BOMYNTRA (Denosumab) 70 mg/mL injection via subcutaneous route. The image depicts a person holding a syringe to inject into the forearm, with a close-up inset highlighting syringe details and an arrow indicating injection direction.*
FDA Label Image

Figure D (Tra1b 0002 05)

Figure D (Tra1b 0002 05)
An instructional diagram showing how to administer a subcutaneous injection using a prefilled syringe of BOMYNTRA (denosumab) 70 mg/mL. The illustration depicts a hand holding the syringe with its cap being removed, positioned to inject into the subcutaneous tissue, likely on the arm.*
FDA Label Image

Figure 1 (Tra1b 0002 06)

Figure 1 (Tra1b 0002 06)
A line graph depicting corrected calcium levels over study days for Denosumab 120 mg (N=23). The x-axis represents study days from baseline (BL) to day 57, with sample sizes indicated below. The y-axis shows corrected calcium levels in mmol/L on the left and mg/dL on the right. Data points connected by dashed lines with error bars illustrate a decline from baseline levels, stabilizing around day 10 onwards.*
FDA Label Image

Logo (Tra1b 0002 07)

Logo (Tra1b 0002 07)
The packaging label for BOMYNTRA 70 mg/mL injection by Fresenius Kabi USA, LLC is blue and white. It prominently features the Fresenius Kabi logo at the top left, with the product name BOMYNTRA in bold blue letters. The label states the active ingredient Denosumab and the route of administration as subcutaneous injection.*
FDA Label Image

Principal Display Panel – 120 mg/1.7 mL Pfs Carton Label (Tra1b 0002 08)

Principal Display Panel – 120 mg/1.7 mL Pfs Carton Label (Tra1b 0002 08)
Packaging label for Bomyntra (denosumab-bnht) injection, 120 mg/1.7 mL (70 mg/mL) in a single-dose prefilled syringe for subcutaneous use. The carton, labeled by Fresenius Kabi USA, LLC, includes one syringe and prescribing information. The label states the product is sterile without preservatives and advises administration by a healthcare provider.*
FDA Label Image

Principal Display Panel – 120 mg/1.7 mL Syringe Label (Tra1b 0002 09)

Principal Display Panel – 120 mg/1.7 mL Syringe Label (Tra1b 0002 09)
Label for Bomyntra 120 mg/1.7 mL (70 mg/mL) injection containing denosumab for subcutaneous use only. The product is labeled Rx only and manufactured by Fresenius Kabi USA, LLC. The label includes the NDC 65219-672-01, lot and expiration information, and a barcode.*
FDA Label Image

Principal Display Panel – 120 mg/1.7 mL Carton Label (Tra1b 0002 10)

Principal Display Panel – 120 mg/1.7 mL Carton Label (Tra1b 0002 10)
Packaging label for Bomyntra (denosumab-bnht) injection, 120 mg/1.7 mL (70 mg/mL) in a single-dose vial for subcutaneous use. The label states it is a sterile solution with no preservative and should be administered by a healthcare provider. The labeler is Fresenius Kabi USA, LLC, and the package includes a barcode and QR code for additional information.*
FDA Label Image

Principal Display Panel – 120 mg/1.7 mL Syringe Label (Tra1b 0002 11)

Principal Display Panel – 120 mg/1.7 mL Syringe Label (Tra1b 0002 11)
Label for BOMYNTRA 120 mg/1.7 mL (70 mg/mL) injection, denosumab-bnht, from Fresenius Kabi USA, LLC. The label includes dosing concentration, subcutaneous route, single-dose vial indication, and barcodes with NDC 65219-670-01.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.